Gastrointestinal Cancer | Specialty

Perioperative Therapy in Gastric/GEJ Cancer

June 26th 2018

Gastric/GEJ Cancers: Challenges in Multimodality Care

June 26th 2018

Multidisciplinary Management of Gastric/GEJ Cancers

June 26th 2018

Molecular Testing in Metastatic Gastric/GEJ Cancer

June 26th 2018

Optimal Stratification of Gastroesophageal Cancers

June 26th 2018

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

O'Neil Shares Insight on Growing Therapeutic Arsenal for GI Tract NETs

June 25th 2018

Bert H. O’Neil, MD, discusses the prevalence of neuroendocrine tumors and the agents that are used to treat patients who present with them.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

TAS-102 Benefit Consistent in Real-World Study for mCRC

June 22nd 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

O'Reilly Discusses Status of Immunotherapy Research in Pancreas Cancer

June 22nd 2018

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

June 22nd 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Dr. Finn Recaps Second-Line Advancements in HCC

June 22nd 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Atezolizumab Combo Not Superior to Regorafenib for mCRC

June 22nd 2018

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

TAS-102 Prolongs Survival in Phase III Gastric Cancer Study

June 21st 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.

Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers

June 21st 2018

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

June 21st 2018

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

June 21st 2018

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

Conroy Highlights Practice-Changing Findings With Chemo Combo in Pancreatic Cancer

June 21st 2018

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

TAS-120 Shows Promise in Cholangiocarcinoma

June 21st 2018

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients

June 20th 2018

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.